Cartesian Therapeutics, Inc. (RNAC) income statement
RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.30+0.18 (+2.94%)
Close on Nov 18, 2026Market cap $190.61MP/E –Yield –
Cartesian Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -10518.6%
- Net margin
- -10283.8%
- Return on equity, FY2025
- 195.9%
Financial strength
- Current ratio
- 7.48
- Debt to equity
- -0.42
- Debt to assets
- 16.6%
- Cash to current liabilities
- 718.3%
Valuation
- P/E ratio
- –
- Price to sales
- 129.05
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?